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Abstract
Extracellular histones are mediators of inflammation, tissue injury and organ dysfunction. Interactions between circulating histones and vascu-
lar endothelial cells are key events in histone-mediated pathologies. Our aim was to investigate the implication of extracellular histones in the
production of the major vasoactive compounds released by human endothelial cells (HUVECs), prostanoids and nitric oxide (NO). HUVEC
exposed to increasing concentrations of histones (0.001 to 100 lg/ml) for 4 hrs induced prostacyclin (PGI2) production in a dose-dependent
manner and decreased thromboxane A2 (TXA2) release at 100 lg/ml. Extracellular histones raised cyclooxygenase-2 (COX-2) and prostacyclin
synthase (PGIS) mRNA and protein expression, decreased COX-1 mRNA levels and did not change thromboxane A2 synthase (TXAS) expres-
sion. Moreover, extracellular histones decreased both, eNOS expression and NO production in HUVEC. The impaired NO production was related
to COX-2 activity and superoxide production since was reversed after celecoxib (10 lmol/l) and tempol (100 lmol/l) treatments, respectively.
In conclusion, our findings suggest that extracellular histones stimulate the release of endothelial-dependent mediators through an up-regula-
tion in COX-2-PGIS-PGI2 pathway which involves a COX-2-dependent superoxide production that decreases the activity of eNOS and the NO
production. These effects may contribute to the endothelial cell dysfunction observed in histone-mediated pathologies.
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Introduction
Recent studies indicate that histones mediate proinflammatory activ-
ity when are released into extracellular space [1]. In this regard, high
levels of circulating histones in plasma have been detected in trauma-
associated injury [2], ischaemia–reperfusion injuries in kidney [3]
liver [4] and sepsis [5, 6].
Endothelium participates in numerous regulatory functions and
contributes to and is affected by inflammatory processes. It is also
involved in blood coagulation and fibrinolysis, immune response by
modulation of leucocyte interactions with the vessel wall and regula-
tion of vascular tone and blood pressure [7]. Disturbance of the
endothelium functional integrity in response to circulating com-
pounds reflects a first step in many disorders. After pro-inflammatory
stimuli, endothelium undergoes activation characterized by increased
local blood flow, leakage of plasma-protein-rich fluid into the tissues
and recruitment and activation of circulating leucocytes [8].
Endothelium exerts these actions through the release of vasoac-
tive compounds, including prostanoids and nitric oxide (NO), that
control functions of both vascular smooth muscle cells and of circu-
lating blood cells [7].
Cyclooxygenases (COX) are the rate-limiting enzymes in the pro-
duction. COX isoenzyme (COX-1 and COX-2) expression has been
detected in the vascular system [9]. COX-1 is considered the constitu-
tive isoform in endothelium, while COX-2 is induced under pro-
inflammatory conditions. However, both COX share characteristics of
constitutive and inducible enzymes in endothelial cells [10]. On the
other hand, NO is mainly produced by endothelial nitric oxide
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synthase (eNOS) in the vasculature [11]. NO dilates blood vessels
through acting on smooth muscle cells and inhibits platelet aggrega-
tion. NO also decreases leucocyte adhesion by suppressing cell adhe-
sion molecule expression on cell membrane surface, therefore
contributing to quiescence of resting endothelial cells [12].
Endothelial cells exposed to extracellular histones release pro-
inflammatory cytokines, induce tissue factor expression [13] and
increase adhesion molecules in the cell membrane [14]. However, the
vasoactive effect of extracellular histones has been less studied.
Therefore, the aim of this study was to describe the implication of
extracellular histones in the release of the two major vasoactive com-
pounds released by endothelial cells, NO and prostanoids.
Materials and methods
Cell culture and experimental design
Primary human umbilical vein endothelial cell (HUVEC) cultures were
obtained from human umbilical cord from ‘Hospital Clınico Universitario’
of Valencia as previously described [15]. Briefly, umbilical veins were
treated with 1% collagenase (Life Technologies, Carlsbad, CA, USA), and
HUVECs extracted were cultured in specific endothelial growth medium,
EGM-2 (Lonza, Cultek, Barcelona, Spain).
HUVECs from passages 3 to 5 were used in this study. When they
reached confluence, media were changed and cells were exposed during
4 hrs to different calf thymus (CT) histone concentrations (Sigma-
Aldrich, St. Louis, MO, USA): 1, 10, 100 ng/ml and 1, 10, 25, 50 and
100 lg/ml prepared in PBS and free of LPS. In some experiments,
10 lmol/l celecoxib, a specific COX-2 inhibitor (Sigma-Aldrich) and
100 lmol/l tempol (Sigma-Aldrich), a superoxide dismutase mimetic,
were added to HUVEC 1 hr before histone treatments.
Cells were identified as endothelial by their characteristic cobblestone
morphology and the presence of von Willebrand factor by immunofluo-
rescence using a specific antibody (ab6994; Abcam, Cambridge, UK).
Cells used in this study were more than 95% vWF positive.
Cell viability was measured by flow cytometry using propidium iodide
(Immunostep, Salamanca, Spain). Our results showed that extracellular
histones scarcely affect HUVEC viability. Only at higher concentrations,
extracellular histones induce a mortality of 6.4% (50 lg/ml) and 10.9%
(100 lg/ml) respect to non-treated cells.
The investigation conforms to the principles outlined in the Declara-
tion of Helsinki and was approved by the Ethical Committee of Clinical
Research of the INCLIVA, ‘Hospital Clınico Universitario’ of Valencia,
and written informed consent was obtained from all donors.
Nitric oxide measurement
NO production was determined by fluorescence microscopy and
4-amino-5-methylamino-20,70-difluorofluorescein diacetate (DAF-FM
Diacetate) (Life Technologies, Alcobendas, Madrid, Spain) probe. After
3-hrs treatment, DAF-FM was added to culture media and incubated for
45 min. Media were then replaced, and cells were incubated for 15
additional minutes to ensure complete fluorescence probe deacetylation.
NO production was determined by measuring intensity fluorescence
at 515 nm on an inverted fluorescence microscope (Eclipse Ti-S; Nikon
Co, Tokyo, Japan). Three randomly selected pictures per condition
tested were taken, and fluorescence intensity measurements were
recorded using NIS-Elements 3.2 software (Nikon Co). Results are pre-
sented as the mean intensity fluorescence per power field subtracting
the background and were relativized to non-treated cells.
Prostacyclin and thromboxane A2 determination
The amount of PGI2 and TXA2 produced was measured by enzyme immune
assay using commercial EIA kits (Cayman Chemical, Ann Arbor, MI, USA)
as previously described [16]. After treatments, media were collected and
stored at 80°C. Cells were lysed in RIPA buffer (Sigma-Aldrich) for protein
determination, calculated by the Pierce BCA protein assay kit using BSA as a
standard (Thermo Scientific Inc., Rockford, USA).
PGI2 and TXA2 levels were calculated as the concentration of stable
hydrolysis metabolite products, 6-keto-prostaglandin-F1alpha and TXB2,
respectively. Results were expressed as the ratio increases over
untreated control in ng prostanoid/mg protein.
RNA isolation and quantitative real-time PCR
assay (qRT-PCR)
Total RNAwas extracted using TRIzol reagent (Invitrogen, Barcelona, Spain)
following the manufacturer’s instructions. Reverse transcription of 200 ng
of total RNA was carried out using High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA) using Mastercycler
Eppendorf Thermocycler (Eppendorf, Hamburg, Germany). The mRNA
levels were determined by qRT-PCR analysis using an ABI Prism 7900 HT
Fast Real-Time PCR System (Applied Biosystems). Gene-specific primer
pairs and probes were purchased from Thermo Fisher (Assay-on-Demand)
for eNOS (Hs01574659_m1), COX-1 (Hs00377726_m1), COX-2
(Hs00153133_m1), PGIS (Hs00919949_m1) TXAS (Hs00233423_m1) and
GAPDH (endogenous control, Hs99999905_m1) and were used with Taq-
Man Universal Mastermix (Thermo Fisher, Rockford, IL, USA). PCR condi-
tions were 10 min. at 95°C for enzyme activation, followed by 40 two-step
cycles (15 sec. at 95°C; 1 min. at 60°C). Data were analysed with the SDS
2.2.2 software (Applied Biosystems) according to the 2DDCt method.
Western blot
Treated HUVECs were collected in RIPA buffer (Sigma-Aldrich) containing
protease and phosphatase inhibitors (Roche Diagnostics, Madrid, Spain).
Protein content was measured by the Pierce BCA protein assay kit (Thermo
Scientific Inc.) using BSA as a standard. Equal amounts of protein were then
separated by SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes (Whatman, GE Healthcare Life Sciences, Chicago,
IL, USA). Immunostaining was achieved using specific antibodies: eNOS
(sc-653), COX-1 (sc-19998), COX-2 (sc-19999), PGIS (sc-20933), TXAS
(sc-79181) all from Santa Cruz BioTechnology (Heidelberg, Germany) and
b-actin (Sigma-Aldrich) as loading control. Development was performed per-
oxidase-linked secondary antibodies (Santa Cruz Biotechnology). Luminol
(ECL Western Blotting Detection Reagents, GE Healthcare, Hatfield, and
Hertfordshire, UK) was added onto the membrane, and membranes were
revealed by an image reader LAS-4000 (GE Healthcare, Uppsala, Sweden).
Signal density was analysed with ImageJ software (NIH Image, National
Institutes of Health, Bethesda, MD, USA).
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Superoxide determination
Intracellular superoxide concentration was detected by measuring dihy-
droethidium (DHE) oxidation. DHE enters in the cell and is oxidized by
superoxide to yield ethidium. Binding of ethidium to DNA produces red fluo-
rescence. Histone-treated cells were loaded with 2.5 lmol/l DHE for
30 min. Then, cells were rinsed with PBS and observed under an inverted
fluorescence Nikon Eclipse Ti-S microscope. Fluorescence from three dif-
ferent fields per well was measured (excitation wavelength: 490 nm; emis-
sion wavelength: 610 nm). Fluorescence signals were quantified using NIS-
Elements 3.2 software (Nikon Izasa S.A, L’Hospitalet de Llobregat, Spain).
Statistical analysis
Values are expressed as mean  S.E.M. A one-way analysis of variance
was used to determine the difference between groups. When an interac-
tion effect was found, multiple comparisons were made using the Tukey
method, and ‘post hoc’ test was performed. The significance has been
considered at *P < 0.05, **P < 0.01 and ***P < 0.001, as indicated in
each case. GraphPad Prism v5.0 (GraphPad Software, San Diego, CA,
USA) was used for statistical analysis and graphic representations.
Results
Effect of extracellular histones on the endothelial
production of NO, PGI2 and TXA2
The first objective of this work was to investigate the effect of extracellu-
lar histones on the endothelial production of vasoactive compounds, in
particular the two main vascular prostanoids, PGI2 and TXA2, and NO.
HUVECs were exposed for 4 hrs to increasing concentration of extracel-
lular histones (1, 10 and 100 ng/ml and 1, 10, 25, 50 and 100 lg/ml).
No effect was observed in PGI2 production at low concentrations of
histones from 1 ng/ml to 25 lg/ml. However, the production of PGI2
increased in a dose-dependent manner at 50 and 100 lg/ml (P < 0.05).
This increment was up to 62  8% in cells exposed to 50 lg/ml and up
to 420  97% in cells exposed to 100 lg/ml, compared to non-treated
cells (Fig. 1A). In contrast, the production of TXA2 by histone-treated
HUVEC decreased only at 100 lg/ml (P < 0.001) without changing at
any other concentration assayed (Fig. 1B).
Using the same conditions described above, increasing concen-
trations of extracellular histones resulted in a significant decrease of
NO production only at 50 (22  3%, P < 0.05) and 100 lg/ml
(26  2%, P < 0.01) histones without changes after treatment from
1 ng/ml to 25 lg/ml (Fig. 1C).
Effect of extracellular histones on gene and
protein expression of prostanoid pathway
mRNA and protein expression levels of the enzymes involved in
PGI2 and TXA2 production were determined. Histone-exposed
HUVEC decreased COX-1 mRNA in a dose-dependent manner
(Fig. 2A). At low concentrations of histones, from 10 to 25 lg/ml,
mRNA COX-1 did not change but the expression decreased up to
24  7% when cells were exposed to 50 lg/ml (P < 0.05) and
29  7% when cells were exposed to 100 lg/ml of histones
(P < 0.05). However, COX-2 mRNA expression increased up to
118  19% at 50 lg/ml (P < 0.05) and 379  66% at 100 lg/ml
of histones (P < 0.001).
In the prostanoid pathway, the COX products cyclo-endoperoxides
PGG2 and PGH2 are rapidly converted in the active compounds PGI2
and TXA2 by means of the specific synthases PGIS and TXAS, respec-
tively. Results from quantitative qRT-PCR analysis showed differ-
ences in PGIS mRNA expression, while TXAS mRNA expression
remained unaltered (Fig. 2A). Histone-treated HUVEC increased PGIS
mRNA levels up to 77  5% at 50 lg/ml (P < 0.001) and up to
96  6% at 100 lg/ml histones (P < 0.001). These data were in
accordance with changes observed in PGI2.
Moreover, mRNA expression profile was supported with pro-
tein expression analysis determined by Western blot (Fig. 2B).
HUVEC exposed to histones shown unaltered COX-1 protein
expression (although a tendency to decrease with higher histone
concentrations exists), while COX-2 was significantly increased
when endothelial cells were exposed at 50 and 100 lg/ml his-
tones. COX-2 protein expression increased up to 43  5% at
50 lg/ml histones (P < 0.05) and up to 94  56% at 100 lg/ml
histones (P < 0.01) above control values (Fig. 2B). Regarding
specific synthases, mRNA PGIS levels were accompanied by an
increment in the amount of PGIS protein expression, also at
50 lg/ml (36  4%, P < 0.05) and 100 lg/ml histones (51  6%,
P < 0.01, Fig. 2B). Finally, no changes in TXAS protein expression
were found (Fig. 2B).
Therefore, these results demonstrated that HUVECs exposed to
extracellular histones show a modulation in COX pathway, mainly by
an up-regulation of COX-2 and PGIS that, in turn, could cause an
increase in PGI2 production. In fact, PGI2 production in 50 lg/ml his-
tone-treated endothelial cells in the presence of the selective COX-2
inhibitor celecoxib (10 lmol/l) completely reversed the effect trig-
gered by extracellular histones (Fig. 2C) supporting the involvement
of COX-2 in the observed effect.
Effect of extracellular histones on gene and
protein expression of NO pathway
As described above, extracellular histones decreased NO produc-
tion in HUVEC (Fig. 1C). To evaluate the synthetic pathway of NO,
eNOS mRNA and protein expression were determined in HUVEC
exposed to increasing concentrations of histone during 4 hrs.
eNOS mRNA levels shown a dose-dependent decrease at 50 and
100 lg/ml of histones, 32  5% (P < 0.01) and 38  5%
(P < 0.05), respectively (Fig. 3A), result supported by eNOS pro-
tein expression (Fig. 3B). Relative levels assessed by densitometry
reveal a significant decrease in eNOS protein expression at 50 and
100 lg/ml histones (P < 0.05).
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Role of COX-2 activity in NO production in
histone-treated HUVEC
As stated before, histones affect COX and eNOS pathways. Previous
reports described an interaction between both pathways [17]. To
investigate whether COX activity is related to NO pathway down-regu-
lation, histone-treated HUVECs were incubated with the COX-2 selec-
tive inhibitor celecoxib (10 lmol/l) and eNOS expression was
determined. Results indicated that COX-2 inhibition significantly
reversed the reduction in eNOS protein levels induced by 50 lg/ml
histones (P < 0.05, Fig. 4A).
Moreover, COX have also been described as superoxide (O2
)-
generating enzymes [18]. Thus, we investigated whether COX-2 activ-
ity induced O2
 production in histone-treated HUVEC. Extracellular
histones (50 lg/ml) induced O2
 production (73  11%, P < 0.001)
that was reversed by the inhibitor of COX-2, celecoxib (10 lmol/l,
Fig. 4B), suggesting an involvement of COX-2 in the O2
 production
induced by histones. To further check whether O2
 was affecting
eNOS expression, incubation with the superoxide dismutase mimetic
agent tempol (100 lmol/l) reversed eNOS protein levels in 50 lg/ml
histone-treated endothelial cells (P < 0.05, Fig. 4C).
Finally, the involvement of COX-2-dependent O2
 production in
NO release by histone-treated HUVEC was evaluated. The effect of
COX-2 inhibition counteracted the reduced levels of NO production
induced by 50 lg/ml histones (P < 0.05, Fig. 4D). Similar effect was
observed after treatment with tempol (100 lmol/l), which also abro-
gated NO decreased levels induced by 50 lg/ml extracellular histones
(P < 0.05, Fig. 4D). These results reinforced the role of increased
O2
 produced by COX-2 in decreased NO levels.
Discussion
In the present study, we demonstrated that extracellular histones
are implicated in the release of vasoactive mediators in human
Fig. 1 Extracellular histone-treated HUVEC alter PGI2 and TXA2 release and decrease NO production. (A and B) HUVECs were exposed to different
concentrations of histones for 4 hrs. Cultured medium was then collected, and PGI2 and TXA2 concentration was measured by enzyme immunoas-
say. Data are expressed as mean  S.E.M. of n = 8–10 from three to five independent experiments. (C) HUVEC incubated with different concentra-
tions of histones for 4 hrs were preloaded for 40 min. with the NO probe DAF-FM for NO production determination. Data are expressed as
mean  S.E.M. of n = 6–8 from three to five independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 versus histones 0 lg/ml.
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vascular endothelial cells. First, histone-treated HUVEC showed an
increment in PGI2 production in a dose-dependent manner. For
TXA2 production, the decrease was only significant at 100 lg/ml.
Second, extracellular histones increased COX-2 and PGIS mRNA
and protein expression, decreased COX-1 mRNA levels but not
protein expression and did not change TXAS expression. These
results suggest an up-regulation in COX-2-PGIS-PGI2 pathway in
those HUVEC exposed to extracellular histones. Third, extracellular
histones decreased eNOS expression and NO production in
HUVEC. Fourth, we identified COX-2 as an O2
-generating enzyme
when HUVECs were exposed to extracellular histones and provide
new insights on the mechanism by which COX-2 activity may
interact with NO production through O2
- generation. Altogether,
our results suggest a key role of extracellular histones in the
modulation of endothelial-dependent factors, such as prostanoid
and NO production, and may explain endothelial cell dysfunction
observed in histone-mediated pathologies.
Extracellular histones have been implicated in organ injury after
trauma [2], autoimmune diseases [19], ischaemic heart disease [20]
or sepsis [5]. As a consequence of the endothelium location, the
response trigged by endothelial cells to the circulating histone binding
is a crucial event in the development of the histone-induced injuries.
In this regard, it has been recently described that injuries at lungs and
liver induced after extracellular histones challenge are primarily medi-
ated through endothelial damage [21] and induced barrier dysfunc-
tion [22]. Increased calcium influx [23] and up-regulation of adhesion
Fig. 2 Extracellular histones alter HUVEC prostanoid production through up-regulation of COX2-PGI2 pathway. (A) HUVEC were exposed to
10–100 lg/ml of histones for 4 hrs. Relative COX-1, COX-2, PGIS, TXAS expression was determined by qRT-PCR. Data are expressed as
mean  S.E.M. of n = 8–10 from three to five independent experiments. (B) Protein extracts (20 lg protein) from cultured HUVEC incubated at dif-
ferent concentrations of histones for 4 hrs were loaded on SDS-PAGE gels and analysed by Western blotting using anti-COX-1, anti-COX-2, anti-
PGIS and anti-TXAS. b-actin was used as loading control. One representative experiment of three performed is shown. Relative levels assessed by
densitometry are presented. (C) HUVECs were exposed to 50 lg/ml of histones (50H) for 4 hrs after pre-incubation with celecoxib (CEL), a specific
COX-2 inhibitor. Cultured medium was then collected, and PGI2 concentration was measured by enzyme immunoassay. Data are expressed as
mean  S.E.M. of n = 3–4 from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 versus histones 0 lg/ml and ##P < 0.01
versus histones 50 lg/ml.
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molecules [24] have also been observed in histone-treated endothelial
cells.
Extracellular histone concentration has been measured in different
experimental models. For example, 200 lg/ml of circulating histones
was detected in an acute lung injury mice model [25] or 15 lg/ml of
H3 in an E.coli-induced sepsis model in baboons [5]. Moreover, simi-
lar range of circulating histones concentrations has been reported in
patients with blunt traumatic lung injury after 4 hrs (10 to 230 lg/ml)
[2] and has been detected in plasma of human patients with sepsis
(70 lg/ml) [5]. Accordingly, we used a concentration range of extra-
cellular histones (10–100 lg/ml) that showed dose-dependent
changes on the endothelial response studied from 50 lg/ml. Never-
theless, we should note that there exists a discordance in the values
of circulating histones levels and those use in experimental models,
as other authors have reported levels ranging from 0.01 ng/ml to
1600 ng/ml for sepsis and severe sepsis [26, 27]. The wide range of
circulating histones in patients suffering different inflammatory dis-
eases described in previous works strongly suggest the need to
determine the exact amount of toxic histones. In addition, as stated
by Semeraro et al. [28], plasma concentrations may underestimate
the local amount of histones found at specific sites of cellular release,
where they could be much higher.
Our results demonstrate an up-regulation of the COX-2-PGIS
pathway and increased synthesis of PGI2 in response to increasing
concentrations of extracellular histones. Prostanoids are essential
endothelial mediators for maintaining the vascular homeostasis [29].
Among them, PGI2 and TXA2 mediate opposite roles in vascular tone
and platelet aggregation. Importantly, PGI2 is the main prostanoid
synthesized by vascular endothelium, playing a crucial role as regula-
tor of correct vascular function [30]. However, PGI2 overregulation
can produce vasodilation and shock [31]. PGIS is constitutively
expressed in endothelial cells where it couples with COX-1, although
COX-2-dependent PGI2 production by endothelial cells has been
reported to be modulated in vitro by inflammatory cytokines [10].
PGI2 has also been considered as an endothelial mediator having
cytoprotective properties [32]. Different studies have reported that
PGI2 action serves to protect endothelial cells from apoptosis both
in vitro and in vivo conditions [33, 34]. As extracellular histones trig-
gered endothelial cell death using the same concentration range used
in our study [23], the increment in PGI2 release observed could be a
compensatory action.
Regarding NO pathway, extracellular histones significantly
decrease at 50 and 100 lg/ml the production of NO by HUVEC. We
found that NO reduction in histone-treated HUVEC is due, at least in
part, to the decrease in eNOS gene and protein expression. In addition
to its vasodilatory effect, NO has anti-inflammatory function and pro-
tects against vascular injury and leucocyte adhesion to the endothe-
lium [35, 36]. In this regard, decreased NO production levels
observed after extracellular histones exposition were in agreement
with histone-dependent actions observed in endothelial cells, such as
an increased cell adhesion molecules expression on the cell mem-
brane [24] and neutrophil recruitment [37].
Since Salvemini et al. [38] described an interaction of NO and
COX enzymes in 1993, several studies support a potential ‘crosstalk’
between both prostanoid and NO pathways [39, 40]. COX activity reg-
ulation by NO has been described with conflicting results [41, 42]
either as positive or as negative regulation of COX activity, and it
seems to depend on basal levels of NO released and the cell type used
in each study [43]. On the other hand, prostanoid biosynthesis has
been also found to modulate NO production, as ibuprofen, a well-
known COX inhibitor, increased NO production in arterial endothelial
cells [44]. In addition, endothelial cell dysfunction or other NO-deplet-
ing situations have been related to a compensatory PGI2 production
[45]. The interaction between both pathways has also been related to
cellular redox status as reactive oxygen species, such as O2
, can
regulate NO bioavailability [46].
Fig. 3 Extracellular histone-treated HUVECs show decreased eNOS expression. (A) HUVEC exposed to increasing concentrations of histones
(10–100 lg/ml) for 4 hrs. Relative eNOS expression was determined by qRT-PCR. Data are expressed as mean  S.E.M. of n = 5–7 from three to
five independent experiments. (B) Protein extracts (20 lg protein) from cultured HUVEC incubated at different concentrations of histones for 4 hrs
were loaded on SDS-PAGE gels and analysed by Western blotting using anti-eNOS. b-actin was used as loading control. One representative experi-
ment of three performed is shown. Relative levels assessed by densitometry are presented. *P < 0.05 and **P < 0.01 versus 0 lg/ml.
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O2
 are released during COX activity as a consequence of their
ability to co-oxidize substances such as NADPH [18]. In this regard,
COX-2 has been demonstrated to be an important source of vascular
O2
 production under inflammatory conditions [47–49]. In our study,
histone-treated HUVEC showed an increment in COX-2 expression,
along with an enzymatic activity, in accordance with the increased
PGI2 levels observed. Moreover, using celecoxib as a specific inhibi-
tor of COX-2, we demonstrate that COX-2 is involved in O2
 produc-
tion increment induced when HUVECs are exposed to extracellular
histones, consistent with earlier studies using superoxide dismutase
in hepatic endothelial cells under inflammatory conditions [50].
Our findings demonstrate that incubation of histone-treated
endothelial cells with celecoxib restored eNOS expression levels.
These results are in accordance with those obtained by Fleenor
et al. [51] where O2
 depletion restored eNOS expression. In
addition, histone-treated endothelial cells exposed to tempol, a
superoxide dismutase mimetic, also restored eNOS expression
levels, suggesting a role of COX-2-dependent O2
 in the results
observed. We have also shown that inhibition of COX-2 with cele-
coxib and decreases of O2- by tempol restore NO levels induced
by extracellular histones. Similar results were obtained in indo-
methacin-treated ageing aortas where NO bioavailability was
restored after COX inhibition [17].
In conclusion, our findings provided evidence that extracellular
histones induce concentration-dependent changes in the two main
vasoactive mediators, resulting in a decrease in NO levels and a shift
in prostanoid release (Fig. 5). Histone-treated endothelial cells show
higher PGI2/TXA2 ratio through an increment of PGI2 production via
up-regulation of COX-2-PGIS pathway. Moreover, the increase in
intracellular superoxide levels observed in histone-treated HUVEC, at
least in part produced by COX-2 activity, contributes to a decreased
NO bioavailability. Therefore, the molecular mechanisms described in
this work could provide new insight on vascular modulation in
pathologies in which extracellular histones are involved.
Fig. 4 COX-2, through anion superoxide production, is involved in NO production decrease in extracellular histone-treated HUVEC. (A) HUVECs were
exposed to 50 lg/ml of histones (50H) for 4 hrs after 1 hr incubation with celecoxib (CEL), and protein extracts (20 lg protein) were loaded on
SDS-PAGE gels and analysed by Western blotting using anti-eNOS. b-actin was used as loading control. One representative experiment of five per-
formed is shown. Relative levels assessed by densitometry are presented. (B) Intracellular superoxide levels were determined by DHE oxidation as
described in Materials and Methods. Results (mean  S.E.M. of n = 4–5 from three to five independent experiments) (C) Histone (50 lg/ml)-trea-
ted HUVECs (50H) were incubated with tempol (TEM), and protein extracts (20 lg protein) were loaded on SDS-PAGE gels and analysed by Wes-
tern blotting using anti-eNOS. b-actin was used as loading control. One representative experiment of five performed is shown. Relative levels
assessed by densitometry are presented. (D) HUVEC incubated with celecoxib (CEL) and tempol (TEM) and treated with 50 lg/ml of histones (50H)
for 4 hrs were preloaded for 40 min. with the NO probe DAF-FM to NO production determination. Data are expressed as mean  S.E.M. of n = 5–6
from three to four independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 versus histones 0 lg/ml and #P < 0.05; ##P < 0.01 versus
histones 50 lg/ml.
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